You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

Why Speak at BIO?

Frequently Asked Questions

WiFi Information

Complimentary Wireless Internet Connection

Compliments of:

Conferences and Events: 

2013 Participating Companies

Below are the 2013 participating companies. To see the list of 2012 participating companies, click here.
 
4P Therapeutics
5AM Ventures
Accele Biopharma, Inc.
Achaogen, Inc.
ADM Diagnostics, LLC
Affimed Therapeutics AG
Akron Molecules GmbH
Alethia Biotherapeutics Inc.
Alios Biopharma, Inc.
Alta Partners
Altheus Therapeutics, Inc.
Altravax, Inc.
Ambit Biosciences
Ambrx Inc.
America Stem Cell Inc.
Amgen Inc.
AM-Pharma B.V.
Angiochem
Anthrocell Pty
Apposite Capital
Aquilo Capital
Aquinox Pharmaceuticals, Inc.
Armour Therapeutics Inc
Ash Stevens Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca
Asuragen, Inc.
Asymmetry Global Healthcare
ATEL Ventures
Athyrium Capital Management
Atossa Genetics, Inc.
Auspex Pharmaceuticals, Inc
AvidBiotics Corp.
BASF Venture Capital
Bavarian Nordic, A/S
Baxter International Inc
Baxter Ventures
Bay City Capital
BayBio
BDC Capital Healthcare Fund
BEAT Biotherapeutics Corp.
Bellicum Pharmaceuticals, Inc.
Bijan Capital
BioCrea
Biodesy LLC
BioMed Ventures
BiomedTracker
Bio-Path Holdings, Inc.
BioWorld Today
Blaise Group International
Boehringer Ingelheim Pharmaceutical, Inc
Breakout Labs/ Thiel Foundation
Bristol-Myers Squibb
Burrage Capital
Burrill & Company
Business Development Bank of Canada
Business Wire
BVF L.P.
BWS Financial Inc.
CanaccordGenuity
Capital Royalty L.P.
Catalyst Pharmaceutical Partners
Cato BioVentures
Cerecor Inc.
CertiChem, Inc
CG Pharmaceuticals, Inc
Chubb Group of Insurance Companies
Cipher Pharmaceuticals Inc.
Clinical Persona, Inc.
Colo. Inst. for Drug Device & Diag. Dev.
Conatus Pharmaceuticals
Confluence Life Sciences, Inc
Consulate General of Canada
Contrafect
Corium International, Inc
Coyote Pharmaceuticals
Critical Outcome Technologies Inc.
Cureduchenne
Cyclica Therapeutics Inc
CytomX Therapeutics, Inc.
Dalton Pharma Services
Danken Ventures
Dectiva
Dentons
diaDexus, Inc.
DiaMedica
Dicerna Pharmaceuticals
Dillon Capital Strategies
DiscoveryBioMed, Inc
Dorset Capital LLC
EBD Group
EcoR1 Capital, LLC
Edison Investment Research
EGEN, Inc
EicOsis, LLC
ELEISON PHARMACEUTICALS LLC
Eli Lilly and Company
Elsevier Business Intelligence
Elusys Therapeutics
Enso Ventures
Epirus Biopharmaceuticals, Inc.
EPISTAT
Esperion Therapuetics, Inc.
Evotec International GmbH
Fate Therapeutics, Inc.
Fenwick & West LLP
Five Prime Therapeutics
Forest Laboratories, Inc.
FORMA Therapeutics
Four Oaks Partners
FPRT Bio
Franklin Templeton Investments
Frazier Healthcare Ventures
GE capital
Gemmus Pharma Inc.
GeneCentric Diagnostics, Inc
Genenews
GenSpera, Inc.
Georgia State University Research Foundation
GlobeImmune, Inc.
GLYCOMIMETICS, INC.
Greenwich LifeSciences
Halsa Pharmaceuticals
Healthy Living Magazine
Heat Biologics
Helix Ventures
HepSeeVax
Hightech Reports
Horizon Pharma
Hua Medicine
Igenica, Inc
immatics biotechnologies GmbH
Immune Design
IMMUNE Pharmaceuticals Inc
Immunovaccine
INanoBio
Innotrove LLC
Innovus Pharmaceuticals, Inc.
inovation ventures
Inovio Pharmaceuticals
InSymbiosis
Integrium
International Finance Corporation
International Stem Cell Corporation
Inventis Investment Holdings (China) Ltd
Investor Growth Capital
IPF Partners
Jade Therapeutics, Inc.
Janssen Pharmaceutical Companies of John
Jennerex, Inc.
Johnson & Johnson
JT Pharma
Kala Pharmaceuticals
KangLaiTe USA Inc
Karolinska Development AB (publ.)
Kearny Venture Partners
KineMed, Inc
Kissei America, Inc
KMA & Company
Knobbe Martens Olson & Bear LLP
Knoll Capital Management LLC
KPCB
KVP
La Jolla Pharmaceutical Company
Labrys Biologics, Inc.
Latterell Venture Partners
Leading Biosciences, Inc.
Life Science Angels
Life Science Leader
Lion Biotechnologies
Livwel Therapeutics Inc
Longitude Captial
Lumira Capital
MabVax Therapeutics, Inc.
Mast Therapeutics, Inc.
Maverix Biomics, Inc.
MAX BioPharma Inc.
MaxCyte
Medical Technology Stock Letter
MedPanel Capital Advisors
Menogenix, Inc.
Mercadyne Investments, LLC
Merck
Mercury Fund
Mergermarket
Microbiotix, Inc.
Milestone Capital
Mirna Therapeutics, Inc
Mission Bay Capital
Mitsubishi Corporation
Mizuho Securities USA
Mochida Pharmaceutical
Momenta Pharmaceuticals, Inc.
Morgan Lewis & Bockius LLP
Morphochem AG
MP Healthcare Venture Management, Inc.
MPM Capital
Muse Capital
MustangVC
MyeloRx LLC
Nano3D Biosciences, Inc.
Nanofiber Solutions
NEA
NeoStem
Neuraltus Pharmaceuticals, Inc.
New Biology Ventures, LLC
New Enterprise Associates
NEWGEN THERAPEUTICS, INC.
Next Big Thing Investor.com
NGN Capital LLC
NLV
NLVP
NOVARTIS
Novartis Venture Fund
NovelMed Therapeutics, Inc.
Numab AG
Numoda Capital Innovations
Ocera Therapeutics, Inc
OncologyLink news-n-notes
OncoMed Pharmaceuticals, Inc.
OncoSec Medical
Ontario Government
Onyx Pharmaceuticals
Opsona Therapeutics Ltd.
Opus Point Partners
Orange County Research Center
OrbiMed Advisors
Oxford Bioscience Partners
Oxigene
OxThera AB
Palatin Technologies, Inc.
Palo Alto Investors
Parabon NanoLabs
ParinGenix, Inc.
Patrys Limited
Piper Jaffray & Co
Poliwogg
Polynoma
PreScience Labs
Principia Biopharma
Probiodrug AG
Protagonist Therapeutics Inc.
Proteon Therapeutics, Inc.
Purdue Pharma LP
Quest PharmaTech Inc
Questcor Pharmaceuticals, Inc
QVT
Radius Health, Inc
RECARDIO
Regado Biosciences, Inc.
Resverlogix
ROTH Capital Partners
Russo Partners
RXi Pharmaceuticals
S1 Biopharma
S1 Biopharma, Inc.
Sagient Research
San Diego Tech Coast Angels
San Francisco Business Times
SantA Ventures
ScarX Therapeutics
scendiant
Science Futures
Scrip Intelligence
Sensorion
Sernova Corp
Shinyusha Publishing
Sialix
Sirona Biochem
SironRX Therapeutics, Inc.
Slater Technology Fund
Sofinnova Ventures
Sophiris Bio, Corp
Spring Bank Pharmaceuticals
SR One, Limited
Stemina Biomarker Discovery
Stiftelsen Industrifonden
Strategy Signal LLC
Sutro Biopharma, Inc
SVB
Syndax Pharmaceuticals, Inc.
Syzygy Therapeutics
Tavistock Group
Tech Coast Angels
TeraDiscoveries, Inc
The Burrill Report
The Conafay Group
The Life Sciences Report
The Scripps Research Institute
The Trout Group LLC
Theraclone Sciences, Inc
TherapeuticsMD.com
TheraVasc Inc.
Third Rock Ventures
Thorner Ventures
three arch
TissueGene, Inc.
Topica Pharmaceuticals, Inc.
TriplePoint Capital
Tymora Analytical Operations
Tynan Consulting
UCSF
US Venture Partners
Vaccinex
Valence Life Sciences
Vascular Pharmaceuticals
Versant Ventures
Versartis, Inc.
viDA Therapeutics Inc
Viking Therapeutics, Inc.
Visionary Pharmaceuticals
Vista Partners LLC
Vivaldi Biosciences Inc.
Vivo Ventures
VWR International, LLC
Wall Street Journal
WCG
William Harris Investors
WRF Capital
www.carmot.us
Xalud Therapeutics, Inc.
Zafgen
ZIOPHARM Oncology, Inc
Zymeworks Inc.
 
*Updated 9/30/2013
Conferences and Events: 

2014 Program

Click here to download the full program schedule.

Tuesday, October 7, 2014
6:30 a.m. - 5:00 p.m. Registration Desk Opens Monterey
7:00 a.m. - 5:00 p.m. Partnering Desk Opens Sunset Court
7:00 a.m. - 7:55 a.m. Networking Breakfast Sunset Court
8:00 a.m. - 4:55 p.m. Company Presentations Marina
9:00 a.m. - 9:55 a.m. Therapeutic Session
T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets
Twin Peaks North/South
10:30 a.m. - 11:25 a.m. Twin Peaks North/
South
12:00 p.m. - 12:10 p.m. Opening Plenary Lunch
Welcome Remarks from James C. Greenwood, President and CEO, BIO
Twin Peaks North/
South
12:10 p.m. - 12:30 p.m. Opening Plenary Lunch
Ebola Update: A Conversation with Tekmira’s President and CEO, Mark Murray, PhD
Twin Peaks North/
South
12:00 p.m. - 1:25 p.m. Twin Peaks North/South
2:00 p.m. - 2:55 p.m. Fireside Chat with Nick Leschly, President and CEO, bluebirdbio Twin Peaks North/
South
3:30 p.m. - 4:25 p.m.
Business Roundtable
Twin Peaks North/
South
5:00 p.m. - 7:00 p.m. BIO Investor Forum Reception Gold Ballroom

 

Wednesday, October 8, 2014
7:00 a.m. - 4:30 p.m. Registration Desk Opens Monterey
6:30 a.m. - 4:30 p.m. Partnering Desk Opens Sunset Court
7:30 a.m. - 8:25 a.m. Networking Breakfast Sunset Court
8:30 a.m. - 3:25 p.m. Company Presentations Sunset Court
9:00 a.m. - 9:55 a.m.
Therapeutic Session
Twin Peaks North/
South
10:30 a.m. - 11:25 a.m.
Therapeutic Session
Twin Peaks North/
South
12:30 p.m.-1:25 p.m.
Plenary Lunch Session
Sunset Court
2:00 p.m. - 2:55 p.m.
Business Roundtable
Twin Peaks North/
South
3:30 p.m. - 4:25 p.m. Closing Plenary Session
Up, Up, and Away: How Fragile is the Biotech Rally After Five Positive Years?
Sunset Court
4:30 p.m. - 5:30 p.m. Closing Happy Hour Sunset Court

 

Conferences and Events: 

Speaking Opportunities at BIO

2015 Sponsors

We would like to thank the 2015 BIO Investor Forum sponsors for their support.

To learn more about branding opportunities at the 2015 BIO Investor Forum, please contact George MacDougall at gmacdougall@bio.org.


Regional Co-Hosts

 

            

 

Industry Supporters

 

Supporting Bank Sponsors

 

HCW_logo_wtype below_0.jpg

 

 

BIO Double Helix Sponsors

 
         

 

BIO Helix Sponsor

 

Conference Sponsors




 
       
          ITA-LA-Logo.jpg
 
         
           NYSE_logo_R_RGB_100px.jpg
     
 

 

Media Partners

 

 

 

 

 

 

 

 

Conferences and Events: 

Business Roundtables

Topics and panelists subject to change.

Opening Panel: IPO Frenzy – Are the GoGo Markets Here to Stay? The Investor Perspective

12:00 p.m.-1:25p.m., Tuesday, October 8, 2013, Sunset Court

With 31 (and counting) life sciences companies having already placed IPOs on the market in the first 5 months of this year and others lining up for S-1 filings, biotech is buzzing about a revival of the IPO market – Is it a bubble? Will it translate to more funding? This panel will take a look at what this renewed interest will mean and won’t mean for the industry.

Opening Remarks

  • David Thomas, CFA, Director, Industry Research & Programs, BIO

Moderator

  • Eugene Rozelman, Managing Director, Biopharma Investment Banking, Canaccord Genuity

Panelists

  • Mark Charest, Vice President, New Leaf Venture Partners
  • Evan McCulloch, CFA, Portfolio Manager, Franklin Templeton Investments
  • Effie Toshav, Partner, Fenwick & West LLP

Crowdfunding in Healthcare and Biotech - Will it Bridge the "Valley of Death"?

3:30p.m. - 4:25p.m., Tuesday, October 8th, Twin Peaks North/ South

Smaller private companies are constantly in search of capital, but many find it difficult to navigate the step between a “friends & family” round or one with angels and an initial venture round. Crowdfunding has been used in a limited number of examples for life science companies, but where is this pathway heading? How should a company look at opportunities for crowdfunding? The panel will look at life of a small company, as a CEO moderator asks a set of investors and others about both crowdfunding and other pathways.

Moderator

  • Nicholas Franano, MD, Founder, President & CEO, Novita Therapeutics

Panelists

  • Andrew Merickel, PhD, Partner, Knobbe Martens 
  • Deepa Pakianathan, PhD, General Partner, Delphi Ventures 
  • Gregory C. Simon, CEO, Poliwogg 
  • Hemai Parthasarathy, PhD, Scientific Director, Breakout Labs/Thiel Foundation

The New Road to IPO in the Age of the JOBS ACT: The Company Perspective

Wednesday, October 9th: 2:00pm - 2:55pm

Whereas the investors on the Opening Plenary tackled questions about the IPO market and the opportunities it will or will not present for the industry, the biotech CEOs and industry experts on this panel will provide an in-depth look into the key elements for a successful offering. Topics will include how to engage with the Board, investors and the JOBS Act.

Moderator

  • Jeffrey A. Baumel, Partner, Dentons

Panelists

  • Michael Dybbs, PhD, Principal, New Leaf Venture Partners
  • Paul J. Hastings, President and CEO, OncoMed Pharmaceuticals
  • Michael Margolis, RPh, Managing Director, ROTH Capital Partners
  • Steven J Mento, PhD, President and CEO, Conatus Pharmaceuticals

Closing Plenary: Early Stage Venture Investing – Will Current Trends Continue into 2014?

3:30 p.m. - 4:25 p.m., Wednesday, October 9, 2013, Sunset Court

Any early-stage biotech companies looking for funding can readily recognize the challenge. It’s getting harder and harder to secure dollars from the 10 or so venture capital firms left to consider an investment – but these firms exist and some even have success stories to tout. This panel takes a look at the VC firms considering early-stage investments and their investment models.

Moderator

  • Luke Timmerman, Vice President, Life Sciences Initiatives, Xconomy

Panelists

  • Srini Akkaraju, MD, PhD, General Partner, Sofinnova Ventures
  • Brian Atwood, Managing Director, Versant Ventures
  • Alexis Borisy, Partner, Third Rock Ventures
  • David Donabedian, Vice President, Venture Investments, AbbVie Biotech Ventures
  • Andrew J. Schwab, Managing Partner, 5AM Ventures

*as of 9/17. Program updated frequently. Please check back.

Conferences and Events: 

2015 Participating Investors

Below is the list of 2015 participating investment firms and sell side research analysts for the BIO Investor Forum. To apply for complimentary investor registration, click here.

Investment Firms

5 Prime Ventures & Fidelity Biosciences
5AM Ventures
AbbVie, Inc.
Abingworth
Ally Bridge Group
Alta Partners
Aquilo Capital
Aspire Capital Partners
Astellas Venture Management
ATEL Ventures
ATEM Capital
Avalon Ventures
Bailard, Inc.
Baxalta Ventures
Baxter Ventures
Bay City Capital
BDC Capital Healthcare Fund
Bill & Melinda Gates Foundation
BioEngine Technology Development
Bioengine Venture Capital
BioInnovation Capital
Biomark Capital
BioMed Ventures
Birken Capital Partners
Brace Pharma Capital
Brandon Capital Management
Bridge Bank
BVF Partners
Canaan Partners
Capital Midwest Fund
Cato BioVentures
Cenova Ventures
China Health Industry Capital Investment 
China Healthcare Industrial Capital Fund Management (Shanghai) Co., Ltd
Claremont Creek Ventures
Cleveland Clinic Innovations
Codon Capital
Connective Capital
CRG LP
Danken Ventures/Oresund Capital
DEFTA Partners
Diamond BioFund, Inc.
Dorset Capital LLC
EcoR1 Capital
Eon Research Ventures
Esperante
Fapon Capital
Finance Technology Leverage
Frazier Healthcare Vetnures
GE Capital, Life Sciences
GE Ventures
Gradus/ RSJ Private Equity
Granite Investment Partners
Hamilton Lane
Harvest Capital Strategies
HealthCare Royalty Partners
Heights Capital Management
Helix Ventures
Hercules Technology Growth Capital
Hoesgen Investment Partners, Canaccord Genuity
Hovione Capital
Inbio ventures
Inventis Investment Holdings (China) Ltd
IPF Partners
Johnson & Johnson Innovation - JJDC, Inc.
Jump Capital
Juvenile Diabetes Research Foundation International
Katan Family Office
Kearny Venture Partners 
Life Science Angels
Lincoln Park Capital
Longitude Capital
Lumira Capital
Lyfe Capital
MBL Venture Capital Co., Ltd
Medimmune Ventures, Inc.
MedPro Investors
Merieux Developpement
MidCap Financial
Mill Valley Partners
Mission Bay Capital
MIT Angels
Mitsui & Co. Global Investment, Inc.
Moore Venture Partners
Mustang Ventures
NanoDimension
New Leaf Venture Partners
Novo Ventures 
Oberland Capital
OceanIQ Partners
Opus Point Partners
OrbiMed Advisors
ORIX Healthcare Capital
Oxford Finance LLC
Palo Alto Investors
Pappas Ventures
PDL BioPharma, Inc.
PharmaFund LLP
Platform Houston
Potrero
Precision Bioventures
Prevail Partners
Remiges Ventures
RUSNANO USA, Inc.
Sacramento Angels and Chemical Angels Network
Sanderling Ventures
Sofinnova Ventures
Solar Capital
SR One
SSVC Partners
Sunel Securities, Inc.
Synthesis Capital
Tavistock
Tech Coast Angels
The Angels' Forum
The Merchants Financial Group, Ltd.
The University of California
Theravance, Inc.
TPG Biotech
VantagePoint Capital Partners
Venrock
Versant Ventures
Vertex Venture Holdings
Virtus Inspire Ventures
Vivo Capital
Wellchamp Capital Limited
WRF Capital

Sell Side Research Analysts

Aegis Capital
Chardan Capital Markets
J.P. Morgan
JMP Securities
Oppenheimer & Co., Inc.
Wedbush Securities
SunTrust Robinson Humphrey, Inc.
 

*As of 10/16/2015

Conferences and Events: